S100A8 / A9 Promotes Fibrosis in Iatrogenic Laryngotracheal Stenosis
The Laryngoscope · 2026
DOI: 10.1002/lary.70008 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2026. Verfasst von Laura M Mafla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Calgranulin B, Calgranulin A, Tracheal Stenosis, Laryngostenosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: NIDCD NIH HHS, American Laryngological, Rhinological and Otological Society, National Institute on Deafness and Other Communication Disorders.
Abstract (Originalsprache)
Objective
Iatrogenic Laryngotracheal Stenosis (iLTS) is a pathologic narrowing of the laryngotracheal airway secondary to intubation injury. Inflammation plays a critical role in iLTS pathogenesis. However, the local immune mediators promoting inflammation and subsequent fibrosis remain poorly understood. Transcriptomic analysis of iLTS specimens using single‐cell RNA sequencing has revealed increased expression of the damage‐associated molecular pattern (DAMP), S100A8/A9. The goal of this study is to define the role of S100A8/A9 in iLTS pathogenesis in vivo.
Methods
S100A8/A9 expression was assessed using single‐cell RNA sequencing and immunofluorescence in human iLTS and unaffected tracheal controls. To assess the fibrogenicity of S100A8/A9, iLTS‐induced mice were treated with recombinant S100A8/A9 (0.1 mg/kg) or a vehicle control. Fibrosis was assessed by measurement of tracheal lamina propria (LP) thickness and fibrosis‐related gene expression.
Results
Immunofluorescence of human iLTS specimens demonstrated increased expression of S100A8/A9 in the LP compared to controls. In iLTS‐induced mice, S100A8/A9 treatment resulted in greater LP thickness compared to control‐treated mice (117.7 ± 23.72 vs. 67.7 ± 33.11 μM, p = 0.03). Gene expression analysis demonstrated a 4.42 ± 0.73 fold increase in Col1a1 expression in S100A8/A9‐treated iLTS mice ( p = 0.01). S100A8/A9's downstream regulatory protein MYD88 is increased in human iLTS and in iLTS mice treated with S100A8/A9.
Conclusion
S100A8/A9 is abundant in human iLTS and promotes fibrosis in a murine model. Targeting S100A8/A9 and its downstream signaling protein MYD88 may be an effective treatment strategy to attenuate iLTS. Investigation into therapies that target S100A8/A9 signaling is warranted. Level of Evidence NA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Laura M Mafla, Raymond J So, Yee Chan-Li, Alexander T Hillel, Kevin M Motz
Förderung
- NIDCD NIH HHS
- American Laryngological, Rhinological and Otological Society
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Mafla, L. M., Abd-Elazem, I., So, R. J., Collins, S. L., Chan-Li, Y., Hillel, A. T., & Motz, K. M. (2026). S100A8 / A9 Promotes Fibrosis in Iatrogenic Laryngotracheal Stenosis. The Laryngoscope. https://doi.org/10.1002/lary.70008
Vancouver
Mafla LM, Abd-Elazem I, So RJ, Collins SL, Chan-Li Y, Hillel AT, et al. S100A8 / A9 Promotes Fibrosis in Iatrogenic Laryngotracheal Stenosis. The Laryngoscope. 2026. doi:10.1002/lary.70008
BibTeX
@article{Mafla2026,
author = {Mafla, Laura M and Abd-Elazem, Ibrahim and So, Raymond J and Collins, Samuel L and Chan-Li, Yee and Hillel, Alexander T and Motz, Kevin M},
title = {S100A8 / A9 Promotes Fibrosis in Iatrogenic Laryngotracheal Stenosis},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.70008}
}
EUVIMED